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There is ample evidence from adoptive transfer 
experiments that the actual number of antigen-
reactive cells present at the site of a delayed 
hypersensitivity skin reaction is very small [1] . 
The large majority of cells infiltrating the lesion 
appear to be immunologically uncommitted, and 
have been attracted to the site by the few antigen-
responding cells or substances produced by these 
cells. It has been suggested that the initial reaction 
of antigen with a few specifically sensitized lym-
phocytes results in the production of chemical 
mediators which, through their biologic activity , 
are capable of recruiting host-inflammatory cells , 
activating them, and keeping them at the site of 
the reaction. 
A number of in vitro models have been devel-
oped which permit isolation of cells potentially 
involved in the cell-mediated immune (CMI) reac-
tion and study of their function and interactions. 
These methods involve culturing sensitized lym-
phocytes with specific antigens or nonspecific 
mitogens and assaying the culture medium from 
these cells for the presence of various biologic 
activities. A list of lymphocyte mediators is shown 
in Table 1. These factors affect the behavior of 
macrophages , polymorphonuclear (PMN) leuko-
cytes, lymphocytes, and other cell types. By virtue 
of their biologic effects, one can see how they may 
play a role in vivo in the expression of CMI 
reactions in the skin , in resistance to infection by 
intracellular facultative organisms, and inflamma-
tion. 
While these substances exert marked biologic 
effects on cells in the microenvironment, they are 
produced in only minute quantities by activated 
lymphocytes. Few of the mediators have been 
purified sufficiently to learn about their structure 
and raise antibodies against them so that their 
Reprint requests to Dr. R. E. Rocklin, Department of 
Medicine, Robert B. Brigham Hospital , 125 Parker Hill 
Avenue, Boston, Massachusetts 02120 . 
Ab breviations: 
cAMP: cyclic 3' ,5'-adenosine monophosphate 
CMI: cell -mediated immune 
CSA: colony-stimulating activity 
DFP: diisopropyl fluorophosphate 
IF: interferon 
LIF: leukocyte inhibitory factor 
LMF: lymphocyte mitogenic factor 
L T: lymphotoxin 
MIF: migration inhibitory factor 
OAF: osteoclast-activating factor 
PEC: peritoneal exudate cells 
PMN : polymorphonuclear 
TF: transfer factor 
detection might be simplified. We do not know how 
many chemically distinct mediators there are , nor 
how many are actually involved in vivo in CMI 
reactions. However, several lymphocyte mediators 
have been partially characterized by physicochem-
ical techniques and shown to be distinct entities, 
having effects on different indicator cells . 
This paper will deal with a description of the 
known characteristics and function of soluble lym-
phocyte factors, their assay systems, possible in 
vivo effects , pharmacologic modulation, and clini-
cal significance. 
FACTORS AFFECTING MACROPHAGES 
Macrophage Migration Inhibitory Factor (MIF) 
The first of the lymphocyte mediators to be 
described was MIF. Many years ago it was shown 
that cells from spleen fragments obtained from 
tuberculous guinea pigs would be inhibited in their 
migration if these cells were first exposed in vitro to 
old tuberculin antigen [2]. The migration of mono-
nuclear cells from explants obtained from normal 
animals was not inhibited when exposed to the 
same antigen. Cells were shown to be directly or 
inherently antigen-sensitive and not reactive 
because of the influence of circulating antibody. 
The explant system was replaced by a more 
quantitative and reproducible method which uti-
lized peritoneal exudate cells obtained from 
immune animals that have been placed in small 
glass capillary tubes [3-5]. Peritoneal exudate cells 
(PEC) consist primarily of macrophages (70-80%) 
and some lymphocytes (10-20%). The capillary 
tubes are placed in chambers which are incubated 
at 37°C for 18 to 24 hr. During this period, the cells 
migrate out of the capillary tube onto the glass 
surface of the chamber. In the presence of a specific 
antigen, sensitized PEC do not migrate as far as 
cells that are not exposed to antigen. The areas of 
cell migration are measured by planimetry and the 
ratio of migration inhibition in the presence of 
antigen to that in the absence of antigen is 
calculated. In this system, MIF is produced by the 
lymphocytes present in the cell suspension and it 
acts upon the macrophages. The effects of MIF on 
macrophages are nonspecific , in that lymphocytes 
can be cultured separately from immune macro-
phages, stimulated with antigen or mitogen and 
shown to release MIF. This material will inhibit 
the migration of macrophages from nonimmune 
animals. 
Human lymphocytes also produce MIF [6, 7] 
which inhibits the migration of human monocytes 
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or guinea-pig macrophages used as indicator cells. 
The production of antigen-induced MIF by human 
and animal lymphocytes is closely associated with 
the presence of in vivo cellular hypersensitivity to 
that antigen. Under some circumstances, however, 
lymphocytes release MIF in the absence of a 
specific immunologic reaction. For example, if 
lymphocytes have been activated in vitro by mito-
gens or other nonspecific stimulants, they produce 
MIF as well as other mediators. MIF production 
can be detected 4 to 6 hr after lymphocytes have 
been activated in vitro. The cells will continue to 
release MIF for as long as 4 days, provided that a 
stimulant is continued. 
MIF is resistant to the effects of heating at 56°C 
for 30 min and is a nondialyzable macromolecule. 
Its activity is not diminished when the material is 
treated with RNase and DNase, but it is inacti-
vated following enzymatic treatment with trypsin 
and chymotrypsin [5]. That MIF is actively syn-
thesized by cells following stimulation was shown 
in experiments where puromycin was used. Pre-
treatment of lymphocytes with puromycin pre-
vented MIF production by lymphocytes. In addi-
tion, puromycin has an effect on macrophages in 
TABLE 1. Products of activated lymphocytes 
Mediators affecting macrophages 
Migtation inhibitory factor (MIF) 
Macrophage activating factor (indistinguishable from 
MIF) 
Chemotactic factor for macrophages 
Mediators affecting polymorphonuclear (PMN) leuko-
cytes 
Chemotactic factors for neutrophils, eosinophils, and 
basophils 
Leukocyte inhibitory factor (LIF) 
Mediators affecting lymphocytes 
Mitogenic factors 
Factors affecting antibody production 
Transfer factor (TF) 
Factors affecting other cell types 
Cytotoxic factors 
Growth inhibitory factors 
Clonal inhibitory factor 
Proliferation inhibitory factor 
Osteoclast-activating factor (OAF) 
Interferon (IF) 
Tissue factor 
Colony-stimulating activity (CSA) 
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that they are no longer able to respond to pre-
formed MIF. Actinomycin-D (an inhibitor of DNA-
dependent RNA synthesis) also prevents lympho-
cytes from elaborating MIF. Agents such as corti-
sone or prednisone do not prevent the lymphocyte 
from producing MIF in vitro in nontoxic doses, 
although they are effective in obliterating the 
delayed type hypersensitivity skin test [8,9]. Their 
effect is probably on the macrophage response to 
preformed MIF. 
The properties of guinea-pig and human MIF are 
compared in Table II. Guinea-pig MIF has the 
properties of an acidic glycoprotein (35,000-55,000 
daltons) while human MIF has the properties of a 
smaller protein (25,000 daltons) . 
Little is known about the interaction of MIF 
with its receptor on the macrophage membrane. 
Early studies showed that macrophages incubated 
with trypsin initially failed to respond to MIF but 
after 24 hr regained their ability to do so [5]. This 
suggested that trypsin either altered the macro-
phage membrane or removed receptors for MIF. If 
macrophages are preincubated with MIF -contain-
ing supernatants , then MIF activity is removed, 
presumably by absorption to the cells [10]. This 
does not occur if the macrophages are pretreated 
with trypsin before being exposed to MIF. More 
recently, it was shown that a-L-fucose blocked MIF 
activity on macrophages [11]. Furthermore, mac-
rophages incubated with a-L-fucosidase (which 
cleaves terminal fucose from the oligosaccharide) 
are no longer able to respond to MIF. These 
observations suggest that a-L-fucose is an impor-
tant component of the MIF receptor on the macro-
phage membrane. 
Recent evidence suggests that an active serine 
esterase associated with the macrophage mem-
brane regulates this cell 's response to MIF. Both 
diisopropyl fluorophosphate (DFP) and several 
plasma esterase inhibitors are able to enhance the 
effect of MIF on macrophages [12, 13]. 
Macrophage Activation Factor 
Macrophages obtained from animab; made 
immune by infection exhibit enhanced cunction 
when these cells are cultured in vitro. They appear 
more spread out on glass, are more adhen:nt, more 
phagocytic , and show enhanced bacteri"idal activ-
ity even against organisms that are antigenically 
unrelated to those which have infected the host 
[14, 151. The in vivo state of activation of macro-
phages obtained from animals undergoing an ac-
TABLE II. Comparison of the properties of human and guinea-pig MIF 
Temperature 56°C 
Approximate molecular weight determined by gel filtration 
Disc electrophoresis 
Isopycnic centrifugation on CsCI 
Neuraminidase 
Chymotrypsin 
HumanMIF 
Stable 
23,000 
Albumin 
Protein 
Resistant 
Sensitive 
Guinea-pig MIF 
Stable 
35,000-55,000 
Prealbumin 
Denser than protein 
Sensitive 
Sensitive 
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tive infection can be simulated in vitro by exposing 
macrophages or monocytes from normal individu-
als to lymphocyte mediators . It was first shown in 
the guinea pig that normal macrophages could be 
"activated" after 72 hr of incubation with a mac-
romolecule similar to, if not identical with, that of 
MIF [16, 17]. The changes that were observed 
included increased adherence to their culture ves -
sel, increased rates of phagocytosis , increased 
oxidation of glucose through the hexose monophos-
phate shunt pathway, increased ruffled membrane 
activity, and increased motility. In man, human 
monocytes can be isolated from the blood and 
cultivated in vitro in monolayers [18]. These cells 
can then be exposed to the activating principle 
(MIF); and one can determine, over a period of 
several days , whether or not these blood monocytes 
have become activated. Monolayers of normal 
macrophages can be activated by MIF to kill 
hepatoma cell lines in vitro [19]. Such activated 
macrophages did not kill either syngeneic fibro-
blasts or kidney cells. 
It is of interest that the activation of macro-
phages or monocytes takes several days to occur 
while the inhibition of migration of macrophages 
may be observed within 24 hr. Just how the 
inhibition of macrophage migration is related to 
the later activation of these cells is not known. It 
has been observed that the inhibition of macro-
phage migration is a reversible process; cells ini-
tially inhibited in the first 24 hr may begin to 
migrate again and will actually travel at a faster 
rate than macrophages in control chambers. It may 
be that the initial effect of MIF on macrophage 
function is to change the surface properties of that 
cell so that it becomes more adherent. This is 
observed in one assay as inhibition of migration. 
Later, other metabolic changes occur in the cell so 
that it becomes activated and, in fact, its function 
in g~neral is enhanced. The effects of lymphocyte 
medIators on macrophage function are listed in 
Table III. 
TABLE III. Activation of macrophages in vitro by 
ly mphocyte mediators 
Increased adherence to culture vessel 
Increased ruffled membrane activity 
Increased phagocytosis 
Increased pinocytosis 
Increased membrane adenylate cyclase 
Increased incorporation of glucosamine into membrane 
components 
Decreased electron-dense surface material 
Increased glucose oxidation through hexose monophos-
phate shunt 
Increased levels of lactic dehydrogenase in cytoplasm 
Decreased levels of certain lysosomal enzymes (acid 
phosphatase, cathepsin-D, ,6-glucuronidase) 
Increased number of cytoplasmic granules 
Enhanced bacteriostasis 
Enhanced tumoricidal activity 
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Macrophage (Monocyte) Chemotactic Factor 
Antigen-activated or mitogen-activated lympho-
cytes elaborate a chemotactic substance which 
selectively attracts macrophages or monocytes 
[20]. The chemotactic assay is carried out using a 
chamber which consists of an upper and lower 
c.ompartn:ent that is separated by a micropore 
fIlter havmg a certain pore size. The suspension of 
macrophages or monocytes is placed in the upper 
co~partment, while the lower compartment con-
tams the ch.emotactic material. Usually, one places 
culture flUId from unstimulated lymphocytes or 
antigen-stimulated or mitogen-stimulated lym-
phocytes into the lower compartment to serve as a 
chemotactic stimulus. The chambers are incu-
bated at 37°C for varying times, and the number of 
cells which migrate through the micropore filter 
from the top side to the bottom surface, ar~ 
counted. The chemotactic activity of the culture 
fluid is assessed morphologically by determining 
the number of cells that have migrated through the 
micropore filter. 
A variation of this assay is one in which the 
indicator macrophages are labeled with a radioac-
tive substance such as 51Cr and two filters instead 
of one are used [21]. After the appropriate incuba-
tion time, the amount of radioactivity present in 
the lower filter is determined. This latter modifica-
tion ~orrelates very well with the morphologic 
countmg of cells and is perhaps more objective. 
The production of macrophage chemotactic fac-
tor, li~e other mediators, is antigen specific. The 
factor IS heat stable after incubation at 56°C for 30 
min. Its molecular weight in the guinea-pig is 
35,000 to 55,000 daltons, and in man appears to be 
between. 12,000 and 25,000 daltons [22, 23] . On 
acryiamide gel electrophoresis, the chemotactic 
activity can be found to migrate in that part of the 
g~l ~ssociated with albumin. Its buoyant density is 
SImIlar to that of pure protein, and it is inactivated 
by treatment with chymotrypsin, but not neuramin-
idase [24]. 
The process of chemotaxis or directed migration 
takes place when the cells are presented with a 
gradient of the chemotactic material. If the chemo-
tactic material is placed in the upper chamber as 
well as being in the lower chamber, the net result is 
a loss of directed movement of the cells towards the 
lower chamber. Furthermore, it has been shown 
that MIF does not interfere with the activity of 
chemotactic factor [22 J. If MIF is placed in the 
upper chamber, the net result is an increased 
movement of the cells towards the lower compart-
ment. When chemotactic factor is placed in the 
upper chamber with the cells and MIF in the lower 
cham ber, the net result is a loss of directed 
movement towards the lower compartment. 
FACTORS WHICH AFFECT PMN LEUKOCYTES 
Leukocyte Inhibitory Factor (LIF) 
. T~e system of PMN leukocyte migration inhibi-
tion m man appears to be analogous to that seen in 
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the macrophage system. PMN leukocytes are in-
hibited in their migration by a soluble material 
termed LIF [25-28]. The effect of LIF appears to be 
solely on PMN leukocyte migration and not upon 
the migration of macrophages. LIF is produced by 
sensitized lymphocytes following incubation with 
specific antigen as well as after stimulation by 
concanavalin A. LIF is assayed using human buffy 
coat cells, as indicated, or by purifying PMN 
leukocytes from the blood and placing them either 
in capillary tubes as in the MIF system or in agar. 
Cell migration is measured at 18 to 24 hr, the 
relative areas of migration are determined and the 
amount of inhibition of cell migration calculated. 
Human LIF is nondialyzable, heat stable at 
56°C for 30 min, and has an approximate molecu-
lar weight on gel filtration of 68,000 daltons [29]. 
Electrophoretically, it has a similar charge to that 
of albumin and has a buoyant density comparable 
to that of protein. It is inactivated by enzymatic 
treatment with chymotrypsin but is resistant to 
neuraminidase. LIF appears to be a protease 
because of its sensitivity to the alkylating effects of 
DFP. In contrast, human MIF is resistant to DFP. 
It is not known at present how LIF affects PMN 
leukocyte function in other respects. 
Chemotactic Factors for Neutrophils, Basophils, 
and Eosinophils 
Sensitized lymphocytes elaborate chemotactic 
factors for all three types of PMN leukocytes [22, 
30-32]. There appear to be two factors which affect 
the directed movement of eosinophils [30, 31 J. One 
of these factors requires the interaction of the 
mediator with specific antigen-antibody complexes 
in order to generate the activity, whereas the other 
factor is active in the absence of antigen-antibody 
complexes. The chemotactic factors have similar 
molecular weights ranging from 24,000 to 55,000 
daltons. The chemotactic factor for neutrophils has 
been separated from that for macrophages [22]. 
The latter two factors have been found to migrate 
in different parts of a gel during electrophoresis. It 
is not clear at the present time, however, whether 
these factors are all distinct materials or the same 
substance having chemotactic activity for multiple 
cell types. These chemotactic factors may playa 
role in various chronic inflammatory conditions or 
in certain types of delayed hypersensitivity reac-
tions such as the Jones Mote (cutaneous basophil 
hypersensitivity) reaction [32]. 
MEDIATORS AFFECTING LYMPHOCYTES 
Lymphocy te Mitogenic Factor (LMF) 
Sensitized lymphocytes, stimulated by specific 
antigen, release into the culture fluid a substance 
that has mitogenic activity for nonsensitized lym-
phocytes [33, 34]. This material induces normal 
lymphocytes to undergo blast transformation and 
incorporate increased amounts of tritiated thymi-
dine into cellular DNA. The culture fluids are 
incubated with nonsensitive lymphocytes for ap-
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proximately 6 days. Cell division and transforma-
tion are monitored either by counting the numbers 
of transformed cells on stained slides or by measur-
ing the incorporation of tritiated thymidine into 
cellular DNA. An increase in cell division is usually 
found in the cultures that have been incubated 
with culture fluids obtained from antigen-
stimulated lymphocytes rather than with culture 
fluids from unstimulated lymphocytes. 
LMF in the guinea-pig is a nondialyzable mac-
romolecule and is heat stable at 56 °C for 30 min . It 
is resistant to treatment with RN ase and DN ase as 
well as to treatment with proteolytic enzymes such 
as trypsin [35, 36]. It has a molecular weight of 
approximately 20,000 to 30,000 daltons. While 
LMF is produced within the first 6 hr of culture, it 
is not clear whether DNA synthesis is required for 
the cells to be able to generate the material. 
Mitogenic factors capable of activating or 
recruiting nonsensitive lymphocytes could furnish 
a mechanism for expanding a cellular reaction and 
producing greater amounts of mediators. The exact 
role of LMF in the proliferative response is not 
clear. It may be that the first stage of proliferation 
is initiated after activated lymphocytes have re-
leased LMF. The second stage would be the 
nonspecific activation of other lymphocytes by the 
material. Alternatively , some sensitized lympho-
cytes may proliferate directly in the absence of 
LMF if they have been stimulated by an antigen to 
which they are sensitized. 
Factors That Affect Antiaody Production 
Lymphocytes from several species , following 
stimulation by a specific antigen , have been shown 
to produce soluble factors which modulate anti-
body production [37-39]. In the mouse, a mate-
rial has been described which triggers B-lym-
phocytes to make antibody of the 19S class to 
sheep red blood cells . In addition, factors have 
been reported which also increase IgG and IgE 
antibody production. In man, a material has been 
described which induces B-lymphocytes to prolif-
erate, lose their C3 receptors, increase their protein 
synthesis , and induce production of IgG antibody 
to specific antigens [40). On the other hand, 
soluble factors have been reported in some species 
which suppress antibody production. 
The factors that modulate antibody production 
have not been well characterized, and it is not 
known whether they are the same factor acting at 
different concentrations or several d~stinct mate-
rials . The enhancing factor appears to be a nondi-
alyzable, heat-stable macromolecule. The anti-
body-suppressing factor appears also to be a nondi-
alyzable material with a molecular weight of 25,000 
to 55,000 daltons. This material may provide a 
mechanism by which thymic-derived T -lym-
phocytes and bone marrow-derived B-lymphocytes 
cooperate in the production of antibody to certain 
antigens. It would appear that the B-cell, following 
stimulation by antigen, is not triggered directly to 
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synthesize antibody until it has received a second 
signal from the T-Iymphocyte which may be a 
soluble factor. 
Transfer Factor (TF) 
The ability to transfer delayed hypersensitivity 
in man can be accomplished by means of a 
dialyzable material obtained from sensitized indi-
viduals [41-43]. Sensitized lymphocytes contain a 
small -molecular-weight substance called TF which 
is released either by disrupting the cells or by 
stimulating them with a specific antigen. This 
material has the capability of preparing nonsensi-
tive lymphocytes which are exposed to it to re-
spond to specific antigen by undergoing increased 
DNA synthesis and mediator production. 
TF has a molecular weight of less than 4,000 
daltons, is resistant to treatment by DNase and 
RNase, but is orscinol positive. The mechanism by 
which TF is able to prepare nonsensitized lympho-
cytes to respond to specific antigen is unknown. 
There is some indication that the material may be 
a single-stranded polynucleotide which is either 
informational or may provide some part of a 
receptor for antigen. 
MEDIATORS AFFECTING OTHER CELL TYPES 
Cytotoxic Factors and Growth Inhibitory Factors 
Immune lymphocytes may bring about the cytol-
ysis of certain susceptible target cells in two ways. 
One way involves the lymphocyte attaching di-
rectly to the target cell and by a mechanism which 
is not known, bringing about its lysis . This is 
referred to as direct lymphocyte-mediated cytol-
ysis [44]. A second mechanism involves the release 
of a soluble factor called lymphotoxin (LT), which, 
in the absence of the lymphocyte, may also bring 
about the lysis of certain target cells [45] . This 
phenomenon was first described in' the rat where 
lymph node lymphocytes obtained from sensitized 
animals produced a soluble factor which killed 
normal rat embryo fibroblasts. Subsequently, lym-
photoxic substances have been described in other 
species including man [46, 47]. Guinea-pig L T is 
heat labile, has an estimated molecular weight of 
35,000 to 55,000 daltons, migrates electrophoreti-
cally with albumin, has a buoyant density similar 
to t.hat. of protein, and is inact.ivated by chymo-
trypsin but is resist.ant to neuraminidase [24] . 
Human LT is heat stable, has a molecular weight 
of 80,000 to 90,000 daltons, migrates past albumin 
on electrophoresis, and also has a buoyant density 
similar to that of pure protein [48, 49]. A mecha-
nism by which L T acts on susceptible target cells 
has been postulated [50]. The lymphocyte, having 
been activated by intimate contact with target cell 
membranes, is induced into synthesis of the 
mediator. Following its production, LT binds to 
the target cell membrane where it affects target 
cell lysis. Target cell membrane disruption or 
physical dislodgement promotes the lymphocyte's 
release from the target cell and subsequent cessa-
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tion of LT secretion. This mechanism would in-
hibit an indiscriminate destruction by lympho-
cytes which produce the factor and prevents non-
specific cell damage to the host. The significance of 
in vivo production of LT is unknown. It might be 
related to tumor surveillance, i.e., the destruction 
of neoplastic cells, but how it relates to other 
delayed hypersensitivity reactions is not clear. 
Some activities have been described which, 
rather than causing the lysis of target cells, inhibit 
their growth pattern [51, 52]. Such materials have 
been referred to as proliferation inhibition factor 
and cloning inhibition factor. These materials have 
their effect mainly on certain target cells such as 
human HeLa cells. It has recently been shown that 
all three of these activities may be present in the 
same culture fluid [53]. When present in high 
concentration, the effect of LT is seen. At lower 
levels, a permanent growth inhibition is observed, 
and at still lower concentrations of mediator only a 
temporary inhibition of cell growth is noted. It is 
still not apparent whether the effects of lysis and 
growth inhibition are the result of three separate 
macromolecules or one molecule which can exert 
diverse effects on different cells, depending upon 
its concentration in the medium. 
Interferon (IF) 
Many cell types can be induced by viruses to 
prod uce IF. Lymphocytes may also produce IF -like 
materials when stimulated by viral or nonviral 
inducers. IF -like activity can be detected in the 
culture fluid of both antigen-stimulated and mito-
gen-stimulated lymphocytes [54, 55]. 
The antigen-induced or mitogen-induced IF and 
the viral-induced IF share similar characteristics 
[56]. They are stable at pH 4.0-10.0, stable for 24 
hr at 4 DC, nonsedimentable at 100,000 x g for 2 hr, 
resistant to DNase and RNase, but destroyed by 
trypsin . Their effect is specific for cells of human 
origin. IF production following or during a specific 
immunologic reaction is potentially important to 
the host. Persons who are unable to mount an 
adequate cellular immune response are plagued by 
viral infections and whether or not their lympho-
cytes are able to release IF following stimulation 
by certain antigens may help determine the level of 
their resistance to this type of infection . 
Osteoclast-Activating Factor (OAF) 
There are several substances capable of causing 
the resorption of bone. These include parathyroid 
hormone, prostaglandin E 2 , vitamin D metabo-
lites, and other sterols . Recently, another mediator 
of bone resorption has been identified that may be 
of importance in causing the hypercalcemia seen in 
neoplastic disease or in the pathogenesis of bone 
resorption in dental caries. This material is pro-
duced by lymphocytes in vitro following stimula-
tion by specific antigen or mitogen and is capable 
of forming osteoclasts in bone and activating these 
cells [57]. The technique for measuring bone 
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resorption in organ culture consists of labeling 
shafts of radius or ulna from 19-day-old rat fetuses 
with 45Ca. The culture fluids from lymphocytes are 
incubated with the organ cultures for 4 to 6 days. 
The ratio of 45Ca released into the medium from 
control and treated bone cultures is used as a 
measure of bone resorption. 
Procoagulant Factor Activity (Tissue Factor) 
Antigen-stimulated or mitogen-stimulated lym-
phocytes produce a procoagulant material which 
when incubated with factor VIII-deficient plasma 
is able to correct the prolonged clotting time [58]. 
This material is antigenic ally distinct from factor 
VIII and has been identified as being tissue factor. 
It is very labile and, thus far , has not been well 
characterized. The pathophysiologic importance of 
lymphocyte tissue factor has yet to be determined, 
but it is interesting to consider the various disease 
entities characterized both by lymphocytic infiltra-
tion and pathologic thrombosis such as the rejec-
tion of a transplanted kidney. 
Colony-Stimulating Activity (CSA) 
The differentiation of marrow cells into granulo-
cytes and mononuclear cells in vitro can be accom-
plished by the addition of a colony-stimulating 
factor [59] . While blood monocytes and tissue 
macrophages appear to be a major source of this 
material, recent evidence suggests that lympho-
cytes may also actively produce CSA during an 
immunologic reaction. Mitogen-activated lympho-
cytes from thymus and spleen elaborate CSA after 
4 days in culture . CSA is described as being a 
heat-stable glycoprotein with a molecular weight of 
approximately 40,000 to 60,000 daltons. 
IN VIVO SIGNIFICAN CE OF MEDIATORS 
Skin Reactive Factor 
That products of activated lymphocytes may 
playa role in the expression of delayed hypersensi -
tivity was shown when lymphocyte mediators were 
injected into the skin of normal animals [60]. A 
partially purified preparation of lymphocyte 
mediators derived from antigen-stimulated cells 
caused the accelerated development of a delayed-
type hypersensitivity reaction in the skin of normal 
guinea pigs. The reaction was characterized by the 
development of erythema and induration at 3 to 5 
hr, which reached a peak by 8 to 12 hr, and 
disappeared by 30 hr. Histologically, the lesion 
simulated that of a delayed-type hypersensitivity 
reaction with the infiltrate comprised primarily of 
mononuclear cells . The factor or factors responsi-
ble for this reaction could be destroyed by trypsin 
and papain but not by DNase or RNase [61]. Drugs 
such as puromycin, chlorphensin, and actinomycin 
prevented its production. Cortisone had no effect 
on its production in vitro by lymphocytes , 
although it could prevent the expression of this 
reaction in vivo. Since preparations used to elicit 
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this response contain several mediators including 
MIF, chemotactic factor, LT and mitogenic factor, 
it is not clear at present whether one or a combina-
tion of these is responsible for the development of 
the skin reaction. Some preparations of skin-reac-
tive factor also possess vasoactive properties. 
When injected into the skin, this material will 
induce the extravasation of Evan's blue dye 
between 20 min and 4 hr. The increased permeabil-
ity induced by skin-reactive factor is not blocked 
by inhibitors of histamine or 5-hydroxytryptamine 
but is affected by inhibitors of the kinin system. 
Mac-rophage Disappearance R eaction 
If one injects mineral oil intra peritoneally into 
normal guinea-pigs , there develops over the next 
few days a peritoneal exudate cell population 
characterized primarily by macrophages. If spe-
cific antigen is injected intra peritoneally along 
with the oil in an appropriately sensitized guinea 
pig, the exudate which forms contains considerably 
fewer macrophages . This phenomenon has been 
termed the macrophage disappearance reaction 
and is associated with a delayed hypersensitivity 
state [62, 63]. Culture fluids derived from antigen-
stimulated lymphocytes can substitute for intact 
cells in the elicitation of this phenomenon in vivo . 
This reaction is mediated by a factor similar to if 
not identical with MIF. The mechanism to explain 
this reaction is unknown but may involve the fact 
that the macrophages have become sticky, adhere 
to the peritoneum, and are absent from the exu-
date. 
Mediator Activity Found in S erum 
Since the usual means for eliciting mediator 
production is by culturing lymphocytes in vitro, it 
is interesting that MIF and IF activities can be 
detected in the serum of animals undergoing an 
immunologic reaction [64]. Serum collected from 
animals immunized with bacillus Calmette-
Guerin and then desensitized by administering 
a large dose of old tuberculin antigen intravenously 
was found to contain these activities. When sera 
from desensitized animals were filtered over a 
Sephadex column, both activities were found in 
the same fraction (molecular weight 45 ,000 dal-
tons). 
Effect of Mediators on Lymph Node Architecture 
If the efferent lymph from animals undergoing 
an immunologic reaction is collected, mediator-
like activity may be detected in this fluid [65]. 
MIF -like and mitogenic activity is found in effer-
ent lymph several days after antigen has been 
injected into the draining lymph nodes. In addi-
tion, other changes occur at this time, including 
increased vascular permeability, increased flow 
rate of lymph, and increased output of lympho-
cytes in the efferent lymph. When preformed 
mediators are injected into the afferent lymphat-
ics, similar changes to those that develop in 
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response to antigenic challenge may be observed 
[66]. These changes include increased numbers of 
cells in the efferent lymph as well as paracortical 
distention and germinal center enlargement. It is 
thought that the mediators may in some way cause 
cellular retention by plugging the efferent vessels, 
thus regulating the rate of efflux of these cells . 
CELL TYPES PRODUCING MEDIATORS 
Delayed hypersensitivity reactions are generally 
assumed to be mediated by thymus-dependent 
T -lymphocytes. It has further been assumed that 
antigen-induced production of lymphocyte media-
tors would be the sole function of T -lymphocytes. 
The recent availability of techniques to separate T-
and B-lymphocytes into purified subpopulations 
has permitted an evaluation of which cell types 
produce these substances. Various studies indicate 
that both cell types are capable of producing some 
mediators. For example, both T -cells and B-cells 
are capable of producing MIF, chemotactic factor 
for macrophages, LIF, and IF [67-70]. It appears, 
however, that lymphocyte-mitogenic factor and 
colony-stimulating factor are produced only by 
T -cells. Several of the lymphocyte mediators from 
both B- and T -cells have similar chromatographic 
patterns. Since B-cells apparently produce the 
same mediators as T -cells, a reinterpretation of the 
role of the B-cell in cellular immunity is needed. 
PHARMACOLOGIC MODULATION OF MEDIATOR 
PRODUCTION 
Cyclic 3'-5' -adenosine monophosphate (cAMP) 
plays an important role as a "second messenger" in 
the regulation of intracellular metabolism . In most 
normal secretory cells an increased level of cAMP 
results in increased production of cell products. In 
contrast, the immune system is affected differently 
by cyclic nucleotides. The antigen-induced release 
of histamine from basophils is abrogated by agents 
known to raise intracellular levels of cAMP. It has 
also been shown that certain immunologic reac-
tions, such as lymphocyte-mediated cytotoxicity 
and the inhibition of macrophage migration by 
MIF, are also abrogated by agents which raise 
cAMP levels. Drugs such as isoproterenol, epi-
nephrine, and prostaglandin E 1, which raise 
cAMP levels by stimulating adenylate cyclase, 
and theophylline, which retards its breakdown, 
interfere with the MIF-induced inhibition of 
guinea-pig macrophages [71, 72]. This effect ap-
pears to be on the macrophage response to MIF 
and not due to an inactivation of MIF by the drug. 
The dibutyryl derivative of cAMP is also effective 
in blocking MIF activity on macrophages. There is 
a suggestion that some drugs that elevate levels of 
cAMP also depress the lymphocyte production of 
MIF. 
The vasoactive amine, histamine, also appears 
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to play a role in modulating the lymphocyte re-
sponse to antigen [73]. There is preliminary evi-
dence to suggest that histamine affects the lym-
phocyte production of MIF, but it does not appear 
to affect the macrophage response to preformed 
MIF: The effects of histamine on the lymphocyte 
production of MIF can be blocked by certain types 
of antihistamines (H 2)' but not by others (H 1)' 
Whether the inhibitory effect on MIF production 
by histamine is via its ability to raise cAMP levels 
or by the activation of certain suppressor lympho-
cytes which may subsequently suppress the MIF-
producing cells is not known at present. 
CLINICAL SIGNIFICANCE 
The production of soluble mediators by lympho-
cytes from normal subjects generally correlates 
with the in vivo state of cellular immunity in that 
donor. These substances are not usually produced 
by antigens which fail to elicit a positive delayed 
skin test. Lymphocytes from some patients with 
depressed cellular immunity and cutaneous anergy 
also do not produce these mediators in response to 
antigenic stimulation [74]. For example, lympho-
cytes from some anergic patients with the 
DiGeorge syndrome, sarcoidosis, chronic mucocu-
taneous candidiasis, Wiskott-Aldrich syndrome, 
Hodgkin's disease, and rheumatoid arthritis do not 
produce the mediator MIF. In some cases, how-
ever, the proliferative response to antigens and 
mitogens may be normal, although MIF produc-
tion is depressed. The cutaneous anergy in these 
patients may be due to a lack of mediator produc-
tion (MIF) by their lymphocytes. In other anergic 
patients, MIF production and proliferative re-
sponses are normal, perhaps indicating intact 
lymphocyte function. Abnormalities in macro-
phage function or the inflammatory response 
might explain the anergy observed in these latter 
patients. 
The MIF assay has also been used for the 
detection of sensitized lymphocytes in patients 
with certain diseases whose pathogenesis may 
involve an immune mechanism. Lymphocytes 
from patients with glomerulonephritis, thyroiditis , 
pernicious anemia, multiple sclerosis, and the 
Guillain-Barre syndrome produce MIF in response 
to various tissue antigens. This assay has also been 
used to detect sensitivity to drugs and tumor 
antigens. 
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DISCUSSION 
Turk: Could you comment on the role of antigen-
dependent MIF in delayed hypersensitivity? What role 
do you think cytophilic antibody has in these phenom-
ena, especially in the macrophage disappearance reac-
tion? 
Rocklin: Lymphocytes elaborate two kinds of MIF: 
one factor is antigen independent, i.e., active in the 
absence of the antigen which induced its production, and 
one is antigen-dependent, i.e. , requiring the presence of 
the inducing antigen for its biologic activity. The latter 
material may operate in conjunction with cytophilic 
antibody while the former does not. It is of interest that 
the antigen-dependent MIF has been reported only with 
PPD as the antigen. 
Claman: If what you say is true-that · B-cells can 
make as much or more mediators (such as MIF) as 
T -cells-one would expect that children with the 
DiGeorge syndrome should be able to make normal or 
increased amounts of MIF while children with congenital 
hypogammaglobulinemia should make less MIF (on a 
cell-to-cell basis)! You might have to use mitogens rather 
than antigens to stimulate MIF . Have these studies been 
done? 
Rocklin: While we have shown that highly purified 
subpopulations of B-cells elaborate MIF in response to 
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specific antigen, these studies were carried out in subjects 
with normal T-cell function. Lymphocytes from patients 
with the DiGeorge syndrome, who lack T-cells but have 
normal numbers of B-cells, do not produce MIF. There-
fore, one may conclude that B-cells are capable of 
producing lymphocyte mediators but require normal 
T -cell function in order to do so (T -dependent B-cell 
MIF). 
Kantor: David characterized MIF production from 
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unseparated lymphocytes as a carrier-dependent func-
tion. Is MIF production from isolated B-cells a hap-
ten-specific or carrier specific reaction? 
Rocklin: No evidence has been presented thus far in 
man concerning the hapten-carrier specificity of B-cell 
MIF. In some animal models there is a suggestion that 
the B-cell can be activated to produce MIF by the 
haptenic portion of the antigenic molecule without regard 
to the carrier portion. 
